CAMBRIDGE, Mass., April 9, 2018 /PRNewswire/ -- Merrimack
Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology
company focused on biomarker-defined cancers, today announced that
it will present preclinical data at the 2018 American Association
for Cancer Research (AACR) Annual Meeting, April 14-18, 2018 at McCormick Place North/South
in Chicago. Of particular focus
will be preclinical data on MM-310, an antibody-directed
nanotherapeutic (ADN) that is currently being evaluated in a Phase
1 study in solid tumors.
MM-310 is Merrimack's wholly-owned clinical product candidate
that targets EphA2, a tumor marker shown to be overexpressed in
several solid tumors, including prostate, ovarian, gastric,
pancreatic and lung cancer. MM-310 uses Merrimack's
antibody-directed nanotherapeutic delivery platform and is designed
to provide highly targeted delivery and sustained exposure of a
proprietary docetaxel prodrug at the site of the tumor. This
delivery mechanism may allow for improved antitumor activity and
reduced drug exposure in normal tissues, and could minimize the
hematologic toxicities common with docetaxel or the vascular
toxicity associated with a traditional EphA2-targeted antibody drug
conjugate (ADC) format.
Also highlighted at the conference will be data from other
preclinical programs currently in development.
Poster Sessions
Targeting EphA2 in bladder cancer using a novel
antibody-directed nanotherapeutic
Abstract #: 5771 / Poster
Board #: 16
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibodies, Fusion Proteins, and Related
Biologics
Wednesday, April 18, 2018,
8:00 AM - 12:00 PM CT
Location: McCormick Place South, Exhibit Hall A, Poster Section
35
Understanding chemotherapy-induced replicative stress to
identify rational combination therapies Abstract #: 2830 /
Poster Board #: 20
Session Category: Experimental and Molecular Therapeutics
Session Title: Modulation of DNA Damage and Repair
Monday, April 16, 2018, 1:00 PM - 5:00 PM CT
Location: McCormick Place South, Exhibit Hall A, Poster Section
37
Predicting ligand-dependent tumors from multi-dimensional
signaling features
Abstract #: 1312 / Poster Board #: 5
Session Category: Bioinformatics and Systems Biology
Session Title: Integrative Cancer Biology 2
Monday, April 16, 2018, 8:00 AM - 12:00 PM CT
Location: McCormick Place South, Exhibit Hall A, Poster Section
13
Development of TNF superfamily agonists: 4-1BB ligand fusion
shows anti-tumor activity in vivo Abstract #: 2716 / Poster
Board #: 8
Session Category: Immunology
Session Title: Immune Checkpoints 2
Monday, April 16, 2018, 1:00 PM - 5:00 PM CT
Location: McCormick Place South, Exhibit Hall A, Poster Section
32
About Merrimack
Merrimack is a biopharmaceutical company based
in Cambridge, Massachusetts that is outthinking cancer to
ensure that patients and their families live fulfilling lives. Its
mission is to transform cancer care through the smart design and
development of targeted solutions based on a deep understanding of
cancer pathways and biological markers. All of Merrimack's
development programs, including four clinical studies and six
candidates in preclinical development, fit into its strategy of 1)
understanding the biological problems it is trying to solve, 2)
designing specific solutions and 3) developing those solutions for
biomarker-selected patients. This three-pronged strategy seeks to
ensure optimal patient outcomes. For more information, please visit
Merrimack's website at www.merrimack.com.
Forward Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts, they are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements include any statements about Merrimack's
strategy, future operations, future financial position, future
revenues and future expectations and plans and prospects for
Merrimack, and any other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue" and similar expressions. In
this press release, Merrimack's forward-looking statements include,
among others, statements about the potential effectiveness and
safety profile of MM-310 and Merrimack's ability to translate
preclinical data into future clinical success. Such forward-looking
statements involve substantial risks and uncertainties that could
cause Merrimack's clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the initiation of future clinical trials, availability of data
from ongoing clinical trials, expectations for regulatory
approvals, development progress of Merrimack's companion
diagnostics, availability of funding sufficient for Merrimack's
foreseeable and unforeseeable operating expenses and capital
expenditure requirements, and other matters that could affect the
availability or commercial potential of Merrimack's product
candidates or companion diagnostics. Merrimack undertakes no
obligation to update or revise any forward-looking statements.
Forward-looking statements should not be relied upon as
representing Merrimack's views as of any date subsequent to the
date hereof. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Merrimack's business in general, see the "Risk Factors"
section of Merrimack's Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on March 12, 2018 and the other reports Merrimack
files with the SEC.
Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com
View original
content:http://www.prnewswire.com/news-releases/merrimack-to-present-preclinical-data-at-the-2018-american-association-for-cancer-research-annual-meeting-300625726.html
SOURCE Merrimack Pharmaceuticals, Inc.